US 12,115,159 B2
Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing GPR119 ligand as active ingredient
Mi-Kyung Kim, Suwon-Si (KR); Bo Ram Lee, Yongin-Si (KR); Hansu Park, Suwon-Si (KR); Seung Ho Lee, Yongin-Si (KR); and Yu Na Chae, Yongin-Si (KR)
Assigned to Dong-A St Co., Ltd., (KR)
Appl. No. 17/275,555
Filed by DONG-A ST CO., LTD., Seoul (KR)
PCT Filed Sep. 11, 2019, PCT No. PCT/KR2019/011839
§ 371(c)(1), (2) Date Mar. 11, 2021,
PCT Pub. No. WO2020/055170, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 10-2018-0109219 (KR), filed on Sep. 12, 2018.
Prior Publication US 2022/0047591 A1, Feb. 17, 2022
Int. Cl. A61K 31/506 (2006.01); A23L 33/10 (2016.01); A61P 1/06 (2006.01)
CPC A61K 31/506 (2013.01) [A23L 33/10 (2016.08); A61P 1/06 (2018.01)] 5 Claims
 
1. A method for alleviating, or treating non-alcoholic steatohepatitis, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition, comprising a compound represented by a following chemical formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof, or mixtures thereof as an effective ingredient:

OG Complex Work Unit Chemistry
wherein A is

OG Complex Work Unit Chemistry
R2 is C1-C6 straight or branched-chain alkyl;
B is

OG Complex Work Unit Chemistry
R7 is C1-C6 straight or branched-chain alkyl; and each X is F.